Table 1.
Comparison of clinical and laboratory features between controls and patients.
| Patients (n = 60) | Controls (n=60) | p | |||||||
| Sex | Male Female | 30 (50%) 30 (50%) | 30 (50%) 30 (50%) | 1.00 | |||||
| Localization | Scalp Beard Scalp-beard-nails Scalp-beard Scalp-nails | 30 (50%) 12 (20%) 9 (15%) 5 (8.4%) 4 (6.6%) | |||||||
| Involvement | ≤1 site≥2 sites | 42 (70%) 18 (30%) | |||||||
| Severity of disease | Mild Moderate Severe | 26(46.1%) 24 (38.5%) 10 (15.4%) | |||||||
| Classification of disease S††B*N** | S0B1N0 S1B0N0 S1B0N1 S2B0N0 S2B0N1 S2B1N0 S2B1N1 S5B0N0 B5B2N1 | 12 (19.2%) 23 (38.5%) 2 (3.8%) 5 (7.7%) 2 (3.8%) 5 (7.7%) 2 (3.8%) 2 (3.8%) 7 (11.5%) | |||||||
| Mean | ±SD‡‡ | CV | Range | Mean | CV | Range | P | ||
| Age | years | 28.1 | 5.3 | 19–39 | 28.2 | 5.8 | 19–40 | 0.90 | |
| Duration of disease | months | 4.5 | 1.9 | 1–8 | |||||
| SOD (IU/mL) §§ | Total | 1.6 | ±0.2 | 0.13 | 1.2–1.9 | 1.8 | 0.33 | 0.7–2.8 | 0.035 |
| CAT (IU/mL) † | Total | 20.4 | ±4.8 | 0.24 | 12.8–33.2 | 25.1 | 0.23 | 12.8–38.3 | 0.005 |
| GSH-ST (IU/mL) ‡ | Total | 3.1 | ±0.4 | 0.13 | 2.1–3.9 | 2.5 | 0.24 | 1.4–3.9 | 0.002 |
| MDA (nmol/L) || | Total | 35.1 | ±5.6 | 0.16 | 26.4–45.1 | 23.6 | 0.17 | 17.2–32.3 | <0.0001 |
| IMA (ΔABSU) § | Total | 0.57 | ±0.01 | 0.2 | 0.56–0.6 | 0.52 | 0.38 | 0.5–0.57 | <0.0001 |
* Body, †catalase, ‡glutathione-S-transferase, § ischemia modified albumin, || malondialdehyde, **nails, ††scalp, ‡‡ standard deviation, §§superoxide dismutase. Coefficient of variation (CV) was defined as the ratio of the SD to the mean.